Pathological complete response rates following different neoadjuvant chemotherapy regimens for Operable Breast Cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 843-851

  Zambetti, Milvia ^a,n   Mansutti, Mauro ^b   Gomez, Patricia ^c   Lluch, Ana ^d   Dittrich, Christian ^e   Zamagni, Claudio ^f   Ciruelos, Eva ^g   Pavesi, Lorenzo ^h   Semiglazov, Vladimir ⁱ   De Benedictis, Elena ^a   Gaion, Fernando ^j   Bari, Mario ^k   Morandi, Paolo ^l   Valagussa, Pinuccia ^m   Luca, Gianni ^a,n  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e LBI ACR   (Austria)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h IRCCS   (Italy)

ⁱ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^j Ospedale Civile di Camposampiero   (Italy)

^k Presidio Ospedaliero di Noale ^*  (Italy)

^l SAN BORTOLO HOSPITAL   (Italy)

^m Fondazione Michelangelo   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

Capecitabine; Chemotherapy; Pathological complete remission; PCR; Taxane

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ESTROGEN RECEPTOR;

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LYMPH NODE DISSECTION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PANCYTOPENIA; PARALLEL DESIGN; PERCEPTION DISORDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; ADJUVANT THERAPY; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; NEUTROPENIA; PACLITAXEL; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84865192262     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1660-6     Document Type: Article

References (39)

1. Untch M, von Minckwitz G (2009) Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11:203
2. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100
3. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044
4. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188-194
5. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21:4165-4174
6. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPAR-DUO study of the German breast group. J Clin Oncol 23:2676-2685
7. Gianni L, Baselga J, Eiermann W et al (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715-8721
8. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329
9. Kaufmann M, von Minckwitz G, Bear HD et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927-1934
10. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24:2019-2027
11. Gianni L, Baselga J, Eiermann W et al (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer. J Clin Oncol 27:2474-2481
12. O'Shaughnessy JA (2003) The evolving role of capecitabine in breast cancer. Clin Breast Cancer 4(Suppl 1):S20-S25
13. Gradishar WJ, Meza LA, Amin B et al (2004) Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 22:2321-2327
14. Batista N, Perez-Manga G, Constenla M et al (2004) Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 90:1740-1746
15. Mariani G, Petrelli F, Zambetti M et al (2006) Capecitabine/ cyclophosphamide/methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. Clin Breast Cancer 7:321-325
16. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
17. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381
18. Wieand HS (2005) Randomized phase II trials: what does randomization gain? J Clin Oncol 23:1794-1795
19. von Minckwitz G, Rezai M, Loibl S et al (2010) Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III Gepar-Quattro study. J Clin Oncol 28:2015-2023
20. von Minckwitz G, Kummel S, Vogel P et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551
21. Ellis MJ, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 105(Suppl 1):33-43
22. Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527-1532
23. Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116
24. Dixon JM, Jackson J, Renshaw L et al (2003) Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86:295-299
25. Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244-254
26. Pico C, Martin M, Jara C et al (2004) Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 15:79-87
27. Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024-2031
28. Precht LM, Lowe KA, Atwood M et al (2010) Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 16:362-368
29. Bhargava R, Beriwal S, Dabbs DJ et al (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 116:1431-1439
30. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
31. Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384
32. Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685
33. Pierga JY, Delaloge S, Espie M et al (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122:429-437
34. Buzdar AU, Valero V, Ibrahim NK et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233
35. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al (2009) Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicine for breast cancer: an openlabel, randomised controlled trial. Lancet Oncol 10:1145-1151
36. ATAC Trialists' Group (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
37. BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
38. Smith IE, Dowsett M, Yap YS et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444-2447
39. Gnant M, Mlineritsch B, Stoeger H, et al. on behalf of the Austrian Breast and colorectal cancer study group, Vienna, Austria (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (in press)